Valiant Organics Ltd Q4 FY2023 Concall Summary

Key Takeaways

• Recovery quarter after a bruising year: Revenue and margins rebounded QoQ as the Sarigam unit normalized post-fire, but FY23 profit still fell ~26% YoY, forcing a token ₹1 dividend.
• PAP is the FY24 growth engine: Management expects ₹250–300 cr from PAP this year, scaling from 400 to 700+ tons/month, with full absorption targeted by year-end.
• OAP remains a black box: Trial runs have succeeded but yields are subpar; management has pushed the timeline to "end of Q2" for any update and admits it has been struggling for "a couple of quarters."
• Margin recovery is fragile: Q4 gross margin hit a multi-quarter high on fixed-cost absorption and input tailwinds, but management's FY24 EBITDA target of 18–20% sits well below the 22–25% standardized range.
• What to watch next quarter: Whether PAP hits the 500-ton/month run-rate, any concrete OAP progress, and whether the dyes & pigments demand pickup promised for H2 actually materializes in customer order books.

The PAP Ramp: The Central FY24 Story

• Volume trajectory: PAP production averaged 400 tons/month in Q4; management aims for 500 by end of Q1 FY24, 600 the quarter after, and 700–750 by year-end, implying a near-doubling over the year.
• Revenue contribution: FY24 PAP revenue guided at ₹250–300 cr, rising to ₹300 cr+ in FY25 at full capacity, making it the single largest growth driver in a ₹1,200 cr top-line plan.
• Process decision finalized: Management has abandoned the full continuous process and will proceed with a batch (or semi-continuous) approach, removing one uncertainty around scale-up.
• Pricing risk: Management expects PAP prices to remain stable but acknowledges a possible further ~10% correction, which would pressure the revenue ramp if volumes do not overcompensate.
• Competitive landscape opaque: When asked about China's import share and Indian competitors, management could not quantify imports and offered only that "not much has changed" domestically, leaving the competitive moat unclear.

Chheda: "So China coming back, yes, the prices are going to correct itself 100%, but the demand is something which is very key right now because some of the sectors are not picking up as we were expecting it to pick up."

OAP: The Deferred Promise

• Stuck in development: Trial runs have been completed successfully, but the product yield and quality are not yet at desired levels, preventing commercialization.
• Timeline repeatedly pushed: Management first flagged OAP as a near-term catalyst; it is now unwilling to commit any timeline, saying only that "end of Q2" might bring clarity and that the team has been "facing some trouble" for multiple quarters.
• No revenue in guidance: OAP contributes zero to the FY24 ₹1,200 cr top-line plan, meaning any upside from a breakthrough would be purely incremental, but the base case assumes nothing.
• Investor takeaway: OAP has shifted from a growth catalyst to a show-me story; the market is likely to ascribe zero value until management demonstrates consistent, commercial-scale production.

Mihir Shah: "We've been trying to get this product up and running since a couple of quarters now, but we are facing some trouble. So let's see, right now, I do not have a very strong comment on when it will start, but maybe another quarter end, we'll know better."

Demand Environment: A Two-Speed Recovery

• Agrochemicals stabilized: The fire-related disruption and customer inventory hold-up that depressed agro volumes for two quarters have cleared; the segment is now "smooth" with no further disturbance expected.
• Dyes & pigments still subdued: Industry-wide demand remains weak, particularly due to low European offtake; while Q4 showed a sequential uptick, Q1 FY24 is expected to stay soft, with customers pointing to H2 for a meaningful pickup.
• The Europe transmission channel: Valiant does not export directly to Europe, but its domestic customers depend on European demand, so the geopolitical drag flows through indirectly and has been the "main contributing factor" to the dyes downturn.
• Pharma a bright spot: The newly commercialized Pharma Intermediates plant began selling to Aarti Pharma Labs in February and is expected to contribute ~₹55 cr in FY24, diversifying revenue away from the troubled dyes segment.
• Overall FY24 top-line: Management guided ₹1,200 cr standalone revenue, implying growth from a depressed FY23 base but still below the ₹1,300–1,400 cr peak potential of existing assets.

Margins: Recovering, But Not Yet Healthy

• Q4 gross margin at multi-quarter high: The quarter delivered the best gross margin since June 2021, driven by Sarigam's fixed-cost absorption, operational efficiencies at the PAP plant, and a favorable raw material price environment.
• The contract lag mechanic: Quarterly contracts with pass-through clauses mean that when raw material prices fall, margins expand temporarily; this dynamic, which squeezed margins severely 1–1.5 years ago, is now working in Valiant's favor.
• FY24 EBITDA guided at 18–20%: This is a recovery from the "worst quarters" but remains below the 22–25% standardized range management considers normal, implying the business is not yet pricing at full health.
• Further raw material pass-through not a threat: Management argues that because contracts are already at squeezed levels, any further raw material price declines passed to customers will not compress margins further; margins should remain stable from here.
• Inventory gains minimal: Some inventory gain was booked this quarter from build-up, but management characterized it as not significant, suggesting the margin improvement is mostly operational.

Mihir Shah: "The previous quarters were in fact probably the worst for Valiant. But this is now in recovery mode. Even with the correction in the raw material prices passing on, it will still not squeeze to a great extent."

Segment & Asset Performance

• Peak asset potential: With no further capex, existing assets can generate ₹1,300–1,400 cr; brownfield additions could lift this to ₹1,450–1,500 cr within two years.
• Capex plan: FY24 capex guided at ₹100–110 cr, mostly maintenance, ETP, and debottlenecking, with a partial brownfield component; funded entirely from internal accruals with no new term debt.

Capital Allocation & Subsidiary Watch

• Dividend slashed to ₹1: Full-year profit fell ~26% YoY due to the fire incident and European demand weakness; management called the distribution "conservative" and said it can pay more when conditions improve.
• Debt trajectory: No plans to raise additional term loans; overall debt is expected to decline as capex is funded internally.
• Valiant Advanced Sciences (subsidiary's subsidiary): This entity is exploring a greenfield expansion into a different product category and has filed for a public issue; management declined to provide details, citing separate management.
• Valiant Laboratories (paracetamol): Not expanding significantly; no material callouts.

Arvind Chheda: "See the scenario was not that good this year because of the European situation and our fire incident also. So we cannot take more risk on distribution. When the times are good, we are paying good dividends also and if the things improve, we can give more also."

Guidance & Commitments

Key Metrics